Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Monopar Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Monopar Therapeutics's regulatory disclosures and financial reporting.
RA Capital Management and related entities reported beneficial ownership of 667,632 shares of Monopar Therapeutics common stock, representing 9.99% of the company’s outstanding shares as of December 31, 2025. The RA Capital Healthcare Fund directly holds 667,207 common shares and pre-funded warrants exercisable for up to 1,621,640 additional shares, but a 9.99% beneficial ownership blocker currently allows exercise of only 425 warrant shares. RA Capital, Peter Kolchinsky, and Rajeev Shah are deemed beneficial owners solely for Section 13(d) purposes and certify that the securities are not held to change or influence control of Monopar.
AstraZeneca PLC, through its wholly owned subsidiary Alexion Pharmaceuticals, Inc., has filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Monopar Therapeutics Inc. common stock.
The filing states that Alexion directly holds 522,667 shares of Monopar common stock, representing 7.8% of the outstanding shares, based on 6,682,584 shares outstanding as of October 31, 2025, as reported in Monopar’s Form 10-Q. AstraZeneca PLC and Alexion may each be deemed to have sole voting and sole dispositive power over these shares.
The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Monopar, and are not held in connection with any transaction having that purpose or effect.
Tactic Pharma LLC and affiliated holders filed an amended Schedule 13D to report a major change in their Monopar Therapeutics ownership. Tactic Pharma now reports beneficial ownership of 0 shares and 0.0% of Monopar common stock after a liquidating, pro rata distribution of its holdings to its members on January 28, 2026.
Following this distribution, Chandler Robinson reports beneficial ownership of 307,370 shares, or 4.5% of the common stock, including 6,732 restricted stock units and 152,105 stock options that are exercisable or will vest within 60 days. Michael Brown reports 124,629 shares, or 1.8%, including 18,878 stock options. Percentages are based on 6,682,584 shares outstanding as of September 30, 2025. As of January 28, 2026, the reporting group no longer owns more than five percent of Monopar’s common stock, and this amendment is designated as their exit filing.
Monopar Therapeutics Chief Executive Officer and director Chandler Robinson reported an indirect acquisition of 62,815 shares of common stock on a Form 4. The shares were received at $0 per share through a pro rata liquidating distribution from Tactic Pharma, LLC and are held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. Following this transaction, Robinson also reports 85,718 common shares held directly.
Monopar Therapeutics director reports indirect share distribution. A reporting person who serves as a director of Monopar Therapeutics disclosed an indirect disposition of 43,499 shares of common stock on 12/16/2025 at a stated price of $0 per share, coded as transaction type "J" (other). The filing explains this relates to a pro rata distribution of Monopar shares by Gem Pharmaceuticals, LLC to its members, in which the reporting person states they have no pecuniary interest.
After the transaction, the reporting person reports 567,580 Monopar shares held indirectly through Gem and 93,750 shares held by DMH Business LLC. As a manager of Gem and of DMH Business LLC’s controlling owner, the reporting person may be deemed to share voting and dispositive power over these shares but disclaims beneficial ownership except to the extent of any pecuniary interest.
Monopar Therapeutics director reported receiving additional company shares in an insider transaction. On 12/16/2025, the reporting person acquired 7,710 shares of Monopar Therapeutics common stock at a stated price of $0, coded as transaction type J. After this transaction, the reporting person beneficially owned 13,883 shares, held directly.
According to the explanation provided, the shares were received through a pro rata distribution from Gem Pharmaceuticals, LLC, in which the reporting person is a non-managing member. The filing indicates it was submitted for one reporting person in their capacity as a director of Monopar Therapeutics.
Monopar Therapeutics (MNPR) reported that it furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The notice was made via an 8-K under Item 2.02, with the press release attached as Exhibit 99.1. The company states this information is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except if specifically referenced.
Monopar Therapeutics (MNPR) filed its Q3 2025 10-Q. The company ended September 30, 2025 with cash and cash equivalents of $127.7 million and investments of $16.0 million, lifting total assets to $144.2 million from $60.3 million at year-end 2024. Net loss was $3.44 million for the quarter and $8.52 million year-to-date, driven by R&D of $2.59 million and G&A of $1.50 million in Q3. Interest income contributed $655,473 in Q3 and $2.03 million year-to-date.
Monopar completed a September 2025 capital raise comprising 1,034,433 common shares at $67.67 and pre-funded warrants for 960,542 shares at $67.669, generating approximately $126.9 million in net proceeds after underwriting discounts. The company used $35.0 million to repurchase 550,229 shares at $63.6098 from Tactic Pharma. Shares outstanding were 6,662,930 at September 30, 2025 and 6,682,584 as of October 31, 2025. Management stated it has sufficient funds to meet obligations at least through December 31, 2027.
Monopar Therapeutics (MNPR) furnished an 8‑K under Regulation FD announcing it issued a press release about presenting new data and analyses from the Phase 2 ALXN1840‑WD‑204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025. The press release is included as Exhibit 99.1 and incorporated by reference.
Monopar Therapeutics (MNPR) insider filing: Andrew Cittadine, the company's Chief Operating Officer and a director, reported equity activity dated 09/30/2025. He received 4,327 shares upon vesting and settlement of restricted stock units. To satisfy tax withholding on the vesting, 1,896 shares were surrendered at an indicated price of $81.67 per share.
After these transactions the filing shows beneficial ownership figures reported on the form: 50,185 shares following the acquisition line and 48,289 shares following the withholding line; the form also lists 38,674 restricted stock units/RSU-related shares held following the reported transactions. The form is executed by attorney-in-fact Quan Vu on 10/02/2025.